Go to the list of all blogs
Allana's Avatar
published in Blogs
Jun 18, 2019
TickeronGET DAILY SIGNALS
Critical Retirement Questions You Should Answer

Critical Retirement Questions You Should Answer

Americans are Grossly Underprepared for Retirement. Are You?

Also in this newsletter

  • Healthcare sector ETF (XLV) trending lower since November

  • A.I. found two new patterns!

——————————————————————————————

Why You Need to Revisit Your Retirement Approach Now

Planning for retirement is not a one-size-fits-all process. It means evaluating myriad variables – post-retirement lifestyle, where to retire, cost of living, the rate of inflation, and more – then formulating a plan that considers current earnings and standard of living, in addition to… Read More…

——————————————————————————————

Healthcare sector ETF (XLV) trending lower since November

The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1. But not all stocks and sectors have recovered fully from the December selloff. One sector that has yet to recover fully is the healthcare sector… Read More…

——————————————————————————————

Current Trading Opportunity — Cup-and-Handle Inverse (Bearish)

——————————————————————————————

Current Trading Opportunity —Broadening Wedge Ascending (Bullish)

Related Ticker: XLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

XLV's Indicator enters downward trend

The Aroon Indicator for XLV entered a downward trend on September 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator formed such a pattern. In 137 of the 161 cases the stock moved lower. This puts the odds of a downward move at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 70 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

XLV moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 267 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Market Cap

The average market capitalization across the State Street Health Care Select Sector SPDR ETF (XLV) ETF is 107.05B. The market cap for tickers in the group ranges from 9.23B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is PODD at 9.23B.

High and low price notable news

The average weekly price growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was -2%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 13%. ILMN experienced the highest price growth at 8%, while INCY experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was 20%. For the same stocks of the ETF, the average monthly volume growth was 70% and the average quarterly volume growth was 17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 41
Price Growth Rating: 47
SMR Rating: 59
Profit Risk Rating: 76
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
Ask AI
VS
Compare
VS
Compare
XLV
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
View AI-Driven Trading for XLV
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
One Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Related Blogs

Kroger (KR, $46.26) misses fiscal Q3 earnings expectations, despite revenue beat

Is Altria (MO, $55.73) Buying Cannabis Company Cronos?

Beyond Meat (BYND, $165.95) distribution to be tripled at Walmart

A Number of Packaged Software Firms Saw Insiders Sell Shares in the Last Few Days

ACET

ACET vs VIR: Weighing Two Clinical-Stage Biotech Stocks

View all blogs related to
#Health
Interesting Articles

What is a short position?

What is beta in investing?

Who Establishes a 401(k)?

How to use the On-Balance Volume in trading?

What Are Index Funds? A Comprehensive Insight

View all articles
Interact to see
Advertisement

U-BX Technology Ltd. (UBXG): +79% Surge in 30 Days Signals Insurtech Momentum

UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
UBXG#AdvertisingMarketingServices
Joma Foster, expert
Apr 02, 2026

Why Commercial Vehicle Group (CVGI) Stock Surged +89% in the Last 30 Days

CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
CVGI#AutoPartsOEM
Joma Foster, expert
Apr 02, 2026

XCF Global (SAFX): +104% Surge in 30 Days Amid Capital Raise and Merger Momentum

SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
SAFT#PropertyCasualtyInsurance
Joma Foster, expert
Apr 02, 2026

LeonaBio (LONA): +80% Surge in 30 Days on Pipeline Momentum and Analyst Upgrades

LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
LONA#Biotechnology
Joma Foster, expert
Apr 02, 2026

Lifetime Brands (LCUT): +77% Surge in 30 Days on Earnings Strength and Strong Buy Rating

Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
LCUT#HomeFurnishings
Joma Foster, expert
Apr 01, 2026

Torrid Holdings (CURV): +73% Surge in 30 Days Amid Earnings Beat and Store Optimizations

CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
CURV#ApparelFootwearRetail
Joma Foster, expert
Apr 02, 2026

Blaize Holdings (BZAI): +72% Surge in 30 Days Amid Earnings Strength and AI Edge Momentum

Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
BZAI#PackagedSoftware
Joma Foster, expert
Apr 02, 2026

Comstock Holding Companies (CHCI): +65% Surge in 30 Days on Strong Earnings and Expansion

Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
CHCI#RealEstateDevelopment
Joma Foster, expert
Apr 02, 2026

GE Aerospace (GE) Stock Drops -12% in 30 Days: What's Behind the Pullback?

GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
GE#AerospaceDefense
Alicia, beginner
Apr 01, 2026

Arm Holdings (ARM): +26% Surge in 30 Days on AI Chip Momentum and Analyst Upgrades

ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
ARM#Semiconductors
Alicia, beginner
Apr 02, 2026

Sable Offshore Corp. (SOC): +92% Surge in 30 Days on Pipeline Restart and Analyst Upgrades

Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
SOC#ContractDrilling
Alicia, beginner
Apr 03, 2026

Nabors Industries (NBR): +12% in 30 Days and +58% Quarterly Surge

NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
NBR#ContractDrilling
Alicia, beginner
Apr 01, 2026

Patterson-UTI Energy (PTEN): +23% in 30 Days Amid Earnings Strength and Sector Tailwinds

Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
PTEN#ContractDrilling
Alicia, beginner
Apr 01, 2026

Patterson-UTI Energy (PTEN): What to Expect from the Q1 2026 Earnings Report

As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
PTEN#ContractDrilling
Alicia, beginner
Apr 01, 2026

76% Win Rate, +76.22% Return: How AI Trades Oil & Energy Stocks During Geopolitical Crisis

When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
OXYEOGFANG#OilGasProduction
Apr 01, 2026

+49% Annualized Return: How to Trade Oil & Gas Stocks During War, Sanctions & Energy Shocks with Tickeron's AI Robot

The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
DVNOVVSM#OilGasProduction
Apr 01, 2026

Cheniere Energy Partners (CQP): Navigating LNG Expansion Amid Valuation Caution

From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
CQP#OilGasPipelines
Apr 01, 2026

Regeneron Pharmaceuticals (REGN): Pipeline Catalysts and Growth Drivers in a Competitive Biotech Landscape

In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
REGN#Biotechnology
Apr 01, 2026

argenx SE (ARGX): Strong Buy Consensus Signals +30% Upside Amid 2026 Catalysts

As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
ARGX#Biotechnology
Apr 01, 2026

Alnylam Pharmaceuticals (ALNY): Strong TTR Growth and Pipeline Catalysts Ahead

I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
ALNY#Biotechnology
Apr 01, 2026